Cellectar Biosciences (CLRB) Q2 2026 Earnings Call Transcript
Cellectar Biosciences (CLRB) reported Q2 2026 earnings with $34M in cash, up from $13.2M at year-end 2025. The company raised $31.7M net from a May 2026 financing, with potential for $140M total. R&D expenses increased to $4.6M, while net loss was $6.9M. Clinical data showed promising results for iopofosine I 131 in Waldenstrom's macroglobulinemia, with a 79.2% response rate in post-BTKi patients. The company plans to initiate a Phase 3 trial by late 2026 or early 2027, targeting mid-2027 NDA su
How this was made
The 30-second read
Why it matters
The disclosed financing and trial milestones reduce near‑term liquidity risk but the company remains early‑stage with high execution risk.
Market read
Provides fresh data for traders tracking small‑cap biotech financing and clinical trial catalysts.
What to watch
Supply‑chain risk for actinium isotopes and potential competition in Waldenstrom's macroglobulinemia could constrain upside.
Background
Cellectar Biosciences provided its Q2 2026 earnings call, highlighting cash balance, financing, net loss, and progress on its radiopharmaceutical pipeline.
Ticker impact
Q2 2026 earnings call disclosed $34M cash, $31.7M net financing, $6.9M net loss and detailed clinical trial updates for iopofosine and CLR 125.
Potential modest upside if trial data remains positive; downside risk if FDA delays.
New capital and trial milestones reduce near‑term funding risk, but loss magnitude and early‑stage data keep volatility high.
Market effects
Biotech sector may see slight lift as financing and trial progress signal continued capital availability for radiopharmaceuticals.
U.S. biotech investors could re‑allocate to early‑stage oncology pipelines.
Limited; primarily affects U.S. small‑cap biotech investors.
Counterpoint
Despite fresh cash, the company remains loss‑making with unproven products; a short position may be justified.
Key entities
- CompanyCellectar Biosciences
U.S. biotech developing radiopharmaceuticals for oncology.
- ExecutiveJames Caruso
President and CEO of Cellectar.
